Jeffrey Gross, MD

Dr. Gross is the Co-Founder and Managing Partner of BioGenware, LLC, a start up company specializing in bioengineered design solutions for medical applications, located in Columbia South Carolina. A vitreoretinal surgeon with over 30 years of ophthalmology experience he is the Founder and President of Carolina Retina Center in Columbia, SC with four offices across Central South Carolina. The author of over 50 peer reviewed articles, as well as book chapters and videos, the Principle Investigator on over 30 clinical trials, he frequently lectures on retinal research and topics at major ophthalmology meetings internationally. He was the National Chair for the landmark DRCR Protocol S study comparing intravitreal injections of anti-VEGF to panretinal photocoagulation for proliferative diabetic retinopathy. He is a Fellow of the American Academy of Ophthalmology, and member of the American Society of Retinal Specialists, Retina Society, Macula Society and American Uveitis Society and ARVO. He is also the inventor of the Gross cannula for SubTenons anesthesia in ocular surgery. Dr. Gross invented the concept for Speculet and with Co-Founder John Lowsky BSME, formed BioGenware. All “under one roof” this vertically integrated full-service manufacturing facility creates solutions from concept to prototyping to production parts. The Speculet platform provides a comfortable eyelid speculum designed for intravitreal injections and is suited for additional ocular procedures and surgical applications. Dr. Gross was awarded First Place for this innovation at the Winning Pitch Challenge at ASRS Chicago in 2019 and subsequently invited to speak at the OIS-AAO in San Francisco in 2019.